M
Massimo Tommasino
Researcher at International Agency for Research on Cancer
Publications - 334
Citations - 14170
Massimo Tommasino is an academic researcher from International Agency for Research on Cancer. The author has contributed to research in topics: Cancer & HPV infection. The author has an hindex of 62, co-authored 312 publications receiving 12239 citations. Previous affiliations of Massimo Tommasino include German Cancer Research Center & World Health Organization.
Papers
More filters
Journal ArticleDOI
E7 properties of mucosal human papillomavirus types 26, 53 and 66 correlate with their intermediate risk for cervical cancer development.
Mariam Mansour,Majid Touka,Uzma Hasan,Angelica Bellopede,Anouk Smet,Rosita Accardi,Anne-Sophie Gabet,Bakary S. Sylla,Massimo Tommasino +8 more
TL;DR: The data show that in vitro properties of these E7 proteins correlate with the epidemiological classification of HPV26, 53 and 66 as HPV types with an intermediate risk for cervical cancer development.
Journal ArticleDOI
Dok1 expression and mutation in Burkitt's lymphoma cell lines
TL;DR: The data show that Dok1 expression and structure are affected in a subset of Burkitt's lymphoma samples, suggesting its possible role in this type of cancer.
Journal ArticleDOI
Beta human papillomaviruses and skin cancer.
Journal ArticleDOI
Cutaneous Human Papillomaviruses and the Risk of Keratinocyte Carcinomas.
Dana E. Rollison,Rossybelle P. Amorrortu,Yayi Zhao,Jane L. Messina,Michael J. Schell,Neil A. Fenske,Basil S. Cherpelis,Anna R. Giuliano,Vernon K. Sondak,Michael Pawlita,Sandrine McKay-Chopin,Tarik Gheit,Tim Waterboer,Massimo Tommasino +13 more
TL;DR: In this article, the authors measured baseline cuHPV infection by serology and viral DNA detection in eyebrow hairs (EBH) and forearm skin swabs (SSW) among 1,008 individuals undergoing routine skin cancer screening exams and followed for incidence of basal cell carcinoma (BCC) and cutaneous squamous cell carcinomas (cuSCC).
Journal ArticleDOI
Impact of Human Papillomavirus Vaccination, Rwanda and Bhutan.
Iacopo Baussano,Felix Sayinzoga,Ugyen Tshomo,Vanessa Tenet,Alex Vorsters,Daniëlle A.M. Heideman,Tarik Gheit,Massimo Tommasino,Marie Chantal Umulisa,Silvia Franceschi,Gary M. Clifford +10 more
TL;DR: In this article, the effectiveness of school-based national human papillomavirus vaccination in Rwanda and Bhutan was estimated through urine-based HPV prevalence surveys in schools in 2013-2014 and 2017.